Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin Efficacy in T2D and NAFLD
NCT03910361Phase 4Completed
- Sponsor
- Dong-A ST
- Start
- Apr 2019
- Primary completion
- Jul 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of DA5221-B2 in type 2 diabetes mellitus (T2DM) and non-alcoholic fatty liver disease (NAFLD) (2 arms), sponsored by Dong-A ST. Primary endpoint: Changes from baseline intrahepatic fat at 24 weeks. Started Apr 2019; status: completed.
02
Drugs
DA5221-B2
03
Conditions
type 2 diabetes mellitus (T2DM)non-alcoholic fatty liver disease (NAFLD)
Beyond the preview
Go deeper on NCT03910361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03910361.